BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst consensus estimate of $(2.34) by 10.26 percent. This is a 41.76 percent decrease over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $122.766 million which missed the analyst consensus estimate of $182.020 million by 32.55 percent. This is a 58.48 percent decrease over sales of $295.696 million the same period last year.